Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Short-duration fixed-volume infusion of isatuximab in relapsed/refractory myeloma

Saad Usmani • 29 May 2020
EHA 2020
Multiple Myeloma Antibodies Isatuximab

Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, shares final results of a Phase Ib feasibility/safety study on short-duration fixed-volume isatuximab infusion combination therapy for relapsed/refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Saad Usmani

The value of iwHRMM and wrap-up of the 2025 meeting 2:23
The value of iwHRMM and wrap-up of the 2025 meeting
Saad Usmani • 24 Oct 2025
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty et al. • 15 Jul 2022
iwGPRC5D 2025: highlights from the workshop 2:44
iwGPRC5D 2025: highlights from the workshop
Saad Usmani et al. • 22 Mar 2025
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
Ajai Chari et al. • 4 Nov 2024

Related Videos

IMMUNOPLANT: linvoseltamab immuno-consolidation to drive MRD negativity in newly diagnosed myeloma 2:29
IMMUNOPLANT: linvoseltamab immuno-consolidation to drive MRD negativity in newly diagnosed myeloma
Dickran Kazandjian • 7 Dec 2025
HRQoL in patients with transplant-eligible newly diagnosed myeloma treated with Isa-RVd vs Rvd alone 2:00
HRQoL in patients with transplant-eligible newly diagnosed myeloma treated with Isa-RVd vs Rvd alone
Elias Mai • 6 Dec 2025
IFM2021-01 trial Cohort A: teclistamab + daratumumab in older patients with newly diagnosed myeloma 2:14
IFM2021-01 trial Cohort A: teclistamab + daratumumab in older patients with newly diagnosed myeloma
Salomon Manier • 7 Dec 2025
Bispecific antibodies in myeloma: top trial updates from ASH 2025 2:59
Bispecific antibodies in myeloma: top trial updates from ASH 2025
Hans Lee • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals